<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03711032</url>
  </required_header>
  <id_info>
    <org_study_id>3475-676</org_study_id>
    <secondary_id>MK-3475-676</secondary_id>
    <secondary_id>2018-001967-22</secondary_id>
    <secondary_id>194713</secondary_id>
    <nct_id>NCT03711032</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)</brief_title>
  <official_title>A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Either Persistent or Recurrent Following BCG Induction or That is Naïve to BCG Treatment (KEYNOTE-676)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the antitumor efficacy and safety of pembrolizumab in&#xD;
      combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is&#xD;
      either persistent or recurrent following adequate BCG induction (Cohort A), or that is naïve&#xD;
      to BCG treatment (Cohort B). The primary hypothesis for Cohort A is that the combination of&#xD;
      pembrolizumab plus BCG has a superior complete response rate (CRR) as assessed by central&#xD;
      pathology review compared to BCG in participants with carcinoma in situ (CIS). The primary&#xD;
      hypothesis for Cohort B is that the combination of pembrolizumab plus BCG (either reduced&#xD;
      maintenance or full maintenance) has a superior Event Free Survival (EFS) compared to BCG.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2018</start_date>
  <completion_date type="Anticipated">October 12, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate (CRR) by Blinded Independent Central Review (BICR) (Cohort A)</measure>
    <time_frame>Up to ~3.5 years</time_frame>
    <description>CRR is defined as the percentage of participants with CIS achieving a complete response (CR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-Free Survival (EFS) (Cohort B)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>EFS is defined as the time from randomization until urothelial carcinoma (UC)-defined event, or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EFS (Cohort A)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>EFS is defined as the time from randomization until UC-defined event, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-Free Survival (RFS) (Cohorts A and B)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>RFS is defined as the time from randomization until the first occurrence of any UC recurrence, progression, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (Cohorts A and B)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Specific Survival (DSS) (Cohorts A and B)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>DSS is defined as the time from randomization to death due to bladder cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cystectomy (Cohorts A and B)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>Time to cystectomy is defined as the time from a participant's randomization until the date of cystectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Month EFS Rate (Cohort A)</measure>
    <time_frame>12 months after EFS (up to ~5 years)</time_frame>
    <description>EFS is defined as the time from randomization until UC-defined event, or death due to any cause. The 12-month EFS rate is defined as the percentage of participants with EFS at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) (Cohorts A and B)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>DOR is defined as the time from first documented CR until end of response or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Month DOR Rate (Cohorts A and B)</measure>
    <time_frame>12 months after CR (up to ~4.5 years)</time_frame>
    <description>The 12-month DOR Rate is defined as the percentage of participants with a CR of at least 12 months duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Adverse Events (AEs) (Cohorts A and B)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discontinuing Study Drug Due to AEs (Cohorts A and B)</measure>
    <time_frame>Up to ~5 years</time_frame>
    <description>An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score (Cohorts A and B)</measure>
    <time_frame>Baseline, time of last PRO assessment (up to ~2 years)</time_frame>
    <description>The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the questions &quot;How would you rate your overall health during the past week?&quot; and &quot;How would you rate your overall quality of life during the past week?&quot; are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall outcome. The change from baseline in Global Health Status/Quality of Life (EORTC QLQ-C30 Items 29 and 30) combined score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EORTC-QLQ-C30 Physical Functioning (Items 1-5) Combined Score (Cohorts A and B)</measure>
    <time_frame>Baseline, time of last PRO assessment (up to ~2 years)</time_frame>
    <description>EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EORTC-QLQ-Non-muscle Invasive Bladder Cancer Module 24 (NMIBC24) Total Score (Cohorts A and B)</measure>
    <time_frame>Baseline, time of last PRO assessment (up to ~2 years)</time_frame>
    <description>The EORTC-QLQ-NMIBC24 is a 24-item questionnaire developed to supplement the EORTC QLQ-C30 in high-risk NMIBC patients. Each item is scored out of 4 total points (1=Not at All to 4=Very Much). All responses are transformed from 0 to 100, with a high score indicating more symptoms or problems. The change from baseline in EORTC-QLQ-NMIBC24 total score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in European Quality of Life (EuroQoL)-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Visual Analogue Score (VAS) (Cohorts A and B)</measure>
    <time_frame>Baseline, time of last PRO assessment (up to ~2 years)</time_frame>
    <description>The EQ-5D-5L VAS records the respondent's self-rated health on a 10 cm vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being &quot;the worst health you can imagine&quot; and 100 being &quot;the best health you can imagine&quot;. The change from baseline in EQ-5D-5L VAS will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD) in the EORTC-QLQ-C30 Global Health Status/Quality of Life (Items 29 and 30) Combined Score (Cohorts A and B)</measure>
    <time_frame>Time of last PRO assessment (up to ~2 years)</time_frame>
    <description>EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the questions &quot;How would you rate your overall health during the past week?&quot; and &quot;How would you rate your overall quality of life during the past week?&quot; are scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall outcome. TTD in Global Health Status/Quality of Life is defined as the time from baseline to the first onset of a 10 point or greater decrease from baseline in the Global Health Status/Quality of Life (EORTC QLQ-C30 Items 29 and 30) combined score, with or without subsequent confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in the EQ-5D-5L VAS (Cohorts A and B)</measure>
    <time_frame>Time of last PRO assessment (up to ~2 years)</time_frame>
    <description>The EQ-5D-5L VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being &quot;the worst health you can imagine&quot; and 100 being &quot;the best health you can imagine&quot;. TTD in EQ-5D-5L VAS is defined as the time from baseline to the first onset of a 7 point or greater decrease from baseline in EQ-5D-5L VAS, with or without subsequent confirmation, under a right-censoring rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRR by BICR (Cohort B)</measure>
    <time_frame>Up to ~3.5 years</time_frame>
    <description>CRR is defined as the percentage of participants with CIS achieving a CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-Month EFS Rate (Cohort B)</measure>
    <time_frame>24 months after EFS (Up to ~5 years)</time_frame>
    <description>EFS is defined as the time from randomization until UC-defined event, or death due to any cause. The 24-month EFS rate is defined as the percentage of participants with EFS at 24 months.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">1405</enrollment>
  <condition>High-risk Non-muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>BCG plus Pembrolizumab: Post-induction Cohort A (Arm A-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive BCG (Induction and Maintenance) in combination with 200 mg pembrolizumab administered intravenously (IV) every 3 weeks (Q3W) for 35 doses (~2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG Monotherapy: Post-induction Cohort A (Arm A-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive BCG monotherapy (Induction and Maintenance).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG plus Pembrolizumab: BCG Naïve Cohort B-Reduced Maintenance (Arm B-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive BCG (Induction and reduced Maintenance) in combination with 400 mg pembrolizumab administered IV every 6 weeks (Q6W) for 9 doses (~1 year).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG plus Pembrolizumab: BCG Naïve Cohort B-Full Maintenance (Arm B-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive BCG (Induction and full Maintenance) in combination with 400 mg pembrolizumab administered IV Q6W for 9 doses (~1 year).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG Monotherapy: BCG Naïve Cohort B (Arm B-3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive BCG monotherapy (Induction and Maintenance).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization</description>
    <arm_group_label>BCG plus Pembrolizumab: BCG Naïve Cohort B-Full Maintenance (Arm B-2)</arm_group_label>
    <arm_group_label>BCG plus Pembrolizumab: BCG Naïve Cohort B-Reduced Maintenance (Arm B-1)</arm_group_label>
    <arm_group_label>BCG plus Pembrolizumab: Post-induction Cohort A (Arm A-1)</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG</intervention_name>
    <description>BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy</description>
    <arm_group_label>BCG Monotherapy: BCG Naïve Cohort B (Arm B-3)</arm_group_label>
    <arm_group_label>BCG Monotherapy: Post-induction Cohort A (Arm A-2)</arm_group_label>
    <arm_group_label>BCG plus Pembrolizumab: BCG Naïve Cohort B-Full Maintenance (Arm B-2)</arm_group_label>
    <arm_group_label>BCG plus Pembrolizumab: BCG Naïve Cohort B-Reduced Maintenance (Arm B-1)</arm_group_label>
    <arm_group_label>BCG plus Pembrolizumab: Post-induction Cohort A (Arm A-1)</arm_group_label>
    <other_name>TICE® BCG</other_name>
    <other_name>OncoTICE®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have locally and blinded independent central review (BICR)-confirmed histological&#xD;
             diagnosis of high-risk non-muscle invasive (T1, high grade Ta and/or CIS) UC of the&#xD;
             bladder&#xD;
&#xD;
          -  Has undergone cystoscopy/ transurethral resection of bladder tumor (TURBT) to remove&#xD;
             all resectable disease&#xD;
&#xD;
          -  Has provided tissue for biomarker analysis&#xD;
&#xD;
          -  Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
          -  During the treatment period and for ≥7 days after the last dose of BCG, male&#xD;
             participants are EITHER abstinent from heterosexual intercourse as their preferred and&#xD;
             usual lifestyle and agree to remain abstinent, OR, must agree to use contraception&#xD;
             unless confirmed to be azoospermic&#xD;
&#xD;
          -  Female participants who are not pregnant, not breastfeeding, and either not a woman of&#xD;
             child bearing potential (WOCBP); or are a WOCBP who agrees to use a contraception&#xD;
             method that is highly effective or remains abstinent from heterosexual intercourse&#xD;
             during the treatment period and for ≥7 days after the last dose of BCG or 120 days&#xD;
             after the last dose of pembrolizumab, whichever comes last&#xD;
&#xD;
        BCG Post-induction Cohort (Cohort A) Only&#xD;
&#xD;
          -  Has been treated with one adequate course of BCG induction therapy for the treatment&#xD;
             of HR NMIBC&#xD;
&#xD;
          -  Following adequate BCG induction therapy, must have persistent or recurrent HR NMIBC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of or concurrent locally advanced (i.e., T2, T3, T4) or metastatic UC&#xD;
&#xD;
          -  Has concurrent extra-vesical (i.e, urethra, ureter, renal pelvis) non-muscle invasive&#xD;
             urothelial carcinoma or a history of extra-vesical non-muscle invasive UC&#xD;
&#xD;
          -  Has received prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an&#xD;
             agent directed to another stimulatory or co-inhibitory T-cell receptor&#xD;
&#xD;
          -  Has received prior systemic anti-cancer therapy including investigational agents&#xD;
             within 4 weeks of start of study treatment&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks of start of study treatment&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             or any other form of immunosuppressive therapy within 7 days of start of study&#xD;
             treatment&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires active treatment&#xD;
             within the past 3 years&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis/interstitial lung disease that required&#xD;
             steroids or has current pneumonitis/interstitial lung disease&#xD;
&#xD;
          -  Has one or more of the following contraindications to BCG: prior BCG sepsis or&#xD;
             systemic infection, total bladder incontinence, or an adverse experience to a previous&#xD;
             BCG instillation that resulted in treatment discontinuation and precludes retreating&#xD;
             with BCG&#xD;
&#xD;
          -  Has an active infection or diagnosis requiring systemic antimicrobial therapy&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Has a known history of Hepatitis B or known active Hepatitis C virus infection&#xD;
&#xD;
          -  Has current active tuberculosis&#xD;
&#xD;
          -  Has had an allogenic-tissue/solid organ transplant&#xD;
&#xD;
          -  Has any contraindication(s) to IV contrast or is otherwise unable to have screening&#xD;
             imaging with IV contrast performed&#xD;
&#xD;
        BCG Post-induction Cohort (Cohort A) Only - Has persistent T1 disease following an&#xD;
        induction course of BCG&#xD;
&#xD;
        BCG Naïve Cohort (Cohort B) Only&#xD;
&#xD;
        - Has received any prior treatment with BCG for their NMIBC within the past 2 years prior&#xD;
        to study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alaska Urological Institute dba Alaska Clinical Research Center ( Site 1083)</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic ( Site 1094)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>480-342-6672</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Institute of Urology (AIU) - Northwest ( Site 1096)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>520-618-1010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-794-3421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center ( Site 1061)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-456-8148</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Genesis Research LLC ( Site 1065)</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-602-5005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colorado Clinical Research ( Site 1100)</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>303-996-9649</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center ( Site 1056)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-243-2177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woodlands Medical Specialists, PA ( Site 8002)</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Emory School of Medicine ( Site 1076)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-778-4823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Urology ( Site 1092)</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>678-344-8900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wichita Urology Group ( Site 1086)</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>316-636-6141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Urology ( Site 1099)</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>318-683-0411</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System ( Site 1062)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-8862</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Institute of Urology ( Site 1077)</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>248-786-0467</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Urology Associates ( Site 1055)</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center ( Site 1090)</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>973-971-5373</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey ( Site 1059)</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Peter's Hospital Cancer Care Center ( Site 1087)</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health- Monter Cancer Center ( Site 1080)</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>516-734-8500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 1074)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-501-8206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals of NY ( Site 1078)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>31547841857794</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-State Urologic Services PSC, Inc. ( Site 1091)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>513-841-7555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center ( Site 1066)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Arthur G James Cancer Hospital &amp; Richard J Solove Research Institute ( Site 10</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>614-366-7421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute ( Site 1075)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>971-262-9600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MidLantic Urology ( Site 1071)</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>610-667-0458</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lancaster Urology ( Site 1079)</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>717-431-2285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania ( Site 1088)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-662-2891</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center ( Site 1085)</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8434491010257</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urology Associates [Nashville, TN] ( Site 1072)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>615-250-9268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas, PLLC ( Site 1064)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-580-1485</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Texas Southwestern Medical Center ( Site 1053)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-645-8787</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Fort Worth Cancer Center ( Site 8003)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Plano West ( Site 8001)</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center ( Site 1057)</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>802-656-9926</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia ( Site 1070)</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>757-452-3463</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nothern Cancer Institute ( Site 0003)</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sydney Adventist Hospital ( Site 0001)</name>
      <address>
        <city>Wahroonga</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH Elisabethinen ( Site 0052)</name>
      <address>
        <city>Linz</city>
        <state>Oberosterreich</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4373276777727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ. Klinik f. Urologie Innsbruck ( Site 0051)</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna ( Site 0054)</name>
      <address>
        <city>Vienna</city>
        <state>Wien</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4367761942300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Salzburg ( Site 0053)</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+435725527400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZA University Hospital Antwerp ( Site 0105)</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3238213718</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur Site de Godinne ( Site 0103)</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3281423858</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>O.L.V. Ziekenhuis Aalst ( Site 0106)</name>
      <address>
        <city>Aalst</city>
        <state>Oost-Vlaanderen</state>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3253724378</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares Gent ( Site 0102)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3292469522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent ( Site 0101)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3293322811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Exdeo Clinical Research Inc. ( Site 0165)</name>
      <address>
        <city>Abbotsford</city>
        <state>British Columbia</state>
        <zip>V2T 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6048515667</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Silverado Resarch Inc. ( Site 0155)</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>2505929988</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Horizon Health Network ( Site 0160)</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5068574780</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre ( Site 0153)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4169462246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS du Saguenay-Lac-St-Jean ( Site 0164)</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4185411000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0157)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5142523400x5766</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUS - Hopital Fleurimont ( Site 0152)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8193461110x12827</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - Hotel-Dieu de Quebec ( Site 0151)</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>418525444420414</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIMCA ( Site 1550)</name>
      <address>
        <city>San José</city>
        <state>San Jose</state>
        <zip>10103</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50683893636</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico San Bosco ( Site 0600)</name>
      <address>
        <city>San Jose</city>
        <zip>10103</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50683384787</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital [Tampere Finland] ( Site 0201)</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+358331164621</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou ( Site 1353)</name>
      <address>
        <city>Rennes</city>
        <state>Ille-et-Vilaine</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33299284270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch-Urology department ( Site 1351)</name>
      <address>
        <city>Suresnes</city>
        <state>Loire-Atlantique</state>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33146251961</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HENRI MONDOR HOSPITAL ( Site 1357)</name>
      <address>
        <city>Créteil</city>
        <state>Seine-et-Marne</state>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33145178243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar. Technischen Universitaet Muenchen ( Site 0266)</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+498941402522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Weiden ( Site 0259)</name>
      <address>
        <city>Weiden In Der Oberpfalz</city>
        <state>Bayern</state>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49963033302</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg ( Site 0265)</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4993120132037</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier-Abteilung für Urologie und Kinderurologie ( Site 0262)</name>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496512082680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena ( Site 0252)</name>
      <address>
        <city>Jena</city>
        <state>Thuringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+49-3641-9-329901</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>General University Hospital of Patras ( Site 0302)</name>
      <address>
        <city>Patra</city>
        <state>Achaia</state>
        <zip>265 04</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+302610999791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antikarkiniko Nosokomeio Thessalonikis THEAGENIO ( Site 0303)</name>
      <address>
        <city>Thessaloniki</city>
        <state>Kentriki Makedonia</state>
        <zip>54639</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+302310898721</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Larissa ( Site 0301)</name>
      <address>
        <city>Larissa</city>
        <state>Thessalia</state>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+302413502811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intervasc ( Site 1454)</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50259042511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>INTEGRA Cancer Institute ( Site 1451)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50222790939</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grupo Medico Angeles-Grupo Medico Angeles ( Site 1453)</name>
      <address>
        <city>Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50240492110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem Klinikai Központ-Urológiai Klinika ( Site 1304)</name>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <zip>7621</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>3672507323</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ-Urológiai Klinika ( Site 1303)</name>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36709411312</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 1302)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36308544051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0353)</name>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223902402</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi ( Site 0360)</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390557949920</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osp Generale Reg di Bolzano ( Site 0355)</name>
      <address>
        <city>Bolzano</city>
        <state>Trentino-Sudtirol</state>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393477835206</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori Giovanni Paolo II ( Site 0357)</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Clinicizzato Santissima Annunziata ( Site 0361)</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390871357783</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Martino ( Site 0351)</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele ( Site 0362)</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39022643789</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Buccheri La Ferla Fatebenefratelli ( Site 0352)</name>
      <address>
        <city>Palermo</city>
        <zip>90123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39091479432</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A. Gemelli ( Site 0358)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390630154953</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Verona - Ospedale Civile Maggiore Borgo Trento ( Site 0356)</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390458123876</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hirosaki University Hospital ( Site 0407)</name>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <zip>036-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81172335111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital ( Site 0414)</name>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81899645111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital ( Site 0412)</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81298533900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital ( Site 0403)</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81427788111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yokosuka Kyosai Hospital ( Site 0406)</name>
      <address>
        <city>Yokosuka</city>
        <state>Kanagawa</state>
        <zip>238-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81468222710</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital ( Site 0411)</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81744223051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center ( Site 0401)</name>
      <address>
        <city>Chiba</city>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81432645431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harasanshin Hospital ( Site 0410)</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81922913434</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute ( Site 0413)</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81669451181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital ( Site 0404)</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81666452121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University Hospital ( Site 0409)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81338136111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital ( Site 0405)</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81333531211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 0804)</name>
      <address>
        <city>Songpagu</city>
        <state>Seoul</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230103980</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital ( Site 0801)</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+821099288097</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 0802)</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220720361</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0803)</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre ( Site 1180)</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60379492120</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre ( Site 0453)</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31433876543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC ( Site 0451)</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31107040704</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0455)</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>31887556308</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital ( Site 0553)</name>
      <address>
        <city>Lorenskog</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4767960000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger universitetssykehus ( Site 0555)</name>
      <address>
        <city>Stavanger</city>
        <state>Rogaland</state>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4751518000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Guillermo Almenara Irigoyen ( Site 0601)</name>
      <address>
        <city>La Victoria</city>
        <state>Lima</state>
        <zip>15033</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Militar Central [Lima, Peru] ( Site 0604)</name>
      <address>
        <city>Lima</city>
        <zip>15076</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51997468543</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncosalud ( Site 0603)</name>
      <address>
        <city>Lima</city>
        <zip>Li 41</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51992756559</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwesytecki Szpital Kliniczny we Wroclawiu ( Site 0669)</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48601143281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne ( Site 0679)</name>
      <address>
        <city>Torun</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48563004380</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow ( Site 0668)</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Urologica Praktyka Lekarska Adam Marcheluk ( Site 0654)</name>
      <address>
        <city>Siedlce</city>
        <state>Mazowieckie</state>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48504283093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luxmed Onkologia sp. z o. o. ( Site 0653)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Koscierzynie Sp. z o.o. ( Site 0671)</name>
      <address>
        <city>Koscierzyna</city>
        <state>Pomorskie</state>
        <zip>83-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48607460282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku ( Site 0655)</name>
      <address>
        <city>Slupsk</city>
        <state>Pomorskie</state>
        <zip>76-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48598460340</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LIFTMED ( Site 0652)</name>
      <address>
        <city>Rybnik</city>
        <state>Slaskie</state>
        <zip>44-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center Sp. z o.o. ( Site 0674)</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-848</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48616632513</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>2CA Braga. Centro Clinico Academico ( Site 0705)</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351253027249</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inst. Portugues de Oncologia de Coimbra Francisco Gentil EPE ( Site 0704)</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351239400200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE ( Site 0708)</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351217229892</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHLN Hospital Santa Maria ( Site 0702)</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351217805056</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital CUF Descobertas ( Site 0706)</name>
      <address>
        <city>Lisboa</city>
        <zip>1998-018</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 0701)</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351225084000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Madrid ( Site 0862)</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid, Comunidad De</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914521987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra ( Site 0863)</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fundacio Puigvert ( Site 0864)</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934169700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti ( Site 0852)</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34982296459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Maranon ( Site 0854)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34914269070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria Navarra - Madrid ( Site 0860)</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Madrid ( Site 0859)</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34917878600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal ( Site 0857)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913368263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0866)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34 912 071 876</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe de Valencia ( Site 0855)</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961244188</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel ( Site 1201)</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41615565477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve HUG ( Site 1204)</name>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41223727876</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zurich ( Site 1203)</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41442555440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eskisehir Osmangazi Universitesi Hastanesi ( Site 0953)</name>
      <address>
        <city>Eskisehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905327149696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 0963)</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905323430723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Universitesi ( Site 0959)</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905055250505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0961)</name>
      <address>
        <city>Konya</city>
        <zip>42000</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322679838</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital ( Site 1006)</name>
      <address>
        <city>Inverness</city>
        <state>Highland</state>
        <zip>IV2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4401463706356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Bartholomew s Hospital ( Site 1008)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442078828505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Georges University Hospitals NHS Foundation Trust. ( Site 1005)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442087253362</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Costa Rica</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trials Information</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>programmed cell death receptor 1 (PD-1)</keyword>
  <keyword>programmed cell death ligand 1 (PD-L1)</keyword>
  <keyword>anti-PD-1</keyword>
  <keyword>anti-PD-L1</keyword>
  <keyword>BCG</keyword>
  <keyword>HR NMIBC</keyword>
  <keyword>Patient Reported Outcome (PRO)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

